GI Motility Agents Do Not Need Dedicated CV Safety Studies, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee overwhelmingly opposes CV-specific studies for the class of 5-HT4 receptor agonists, but says Phase III trials should include patients at high risk for events.
You may also be interested in...
CV Safety Requirements For Motility Drugs Could Take Indication-Centric Approach
At a Nov. 17 meeting on 5-HT4 receptor agonists, FDA will ask advisory committee members whether an increased cardiovascular risk would be acceptable depending upon the context of use and whether sponsors need to conduct a dedicated CV study either before or after approval.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.